Calcium and Bone Metabolism Pre- and Post-Kidney Transplantation (original) (raw)

Abstract

Chronic kidney disease (CKD) is associated with significant disturbances in bone and mineral metabolism representing a major cause of skeletal and cardiovascular morbidity, particularly in end-stage CKD. Successful kidney transplantation corrects many of these disturbances, but the degree of improvement is often incomplete, and disorders of bone remodeling may persist or worsen after transplantation. Because the function of a renal graft deteriorates with time, disturbances are likely to reappear within the 10to 12-year life span of a kidney transplant.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (96)

  1. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-36.
  2. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094-105.
  3. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333:166-74.
  4. Kanis JA, Cundy T, Hamdy NAT. Renal osteodystrophy. In: Martin TJ, editor. Metabolic bone disease. Baillieres Clin Endocrinol Metab 1998;2:193-241.
  5. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroid- ism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2007;1-13 [online publication].
  6. Larsson T, Nisbeth U, Ljunggreen O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9.
  7. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-6.
  8. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphospha- temia but accentuates calcitriol deficiency in chronic kidney diseases. J Am Soc Nephrol 2005;16:2205-15.
  9. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44:250-6.
  10. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross- sectional study across latitudes in the United States. Am J Kidney Dis 2005;45:1026-33.
  11. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997;52:3-9.
  12. Kifor O, Moore FD Jr, Wang P, et al. Reduced immunostaining for the extracellular Ca2þ- sensing receptor in primary, uremic hyperparathyroidism. J Clin Endocrinol Metab 1996;81: 1598-606.
  13. Tokumoto M, Tsuruya K, Fukuda K, et al. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 2002;62:1196-207.
  14. Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 1995;310:358-63.
  15. Hamdy NAT. The spectrum of renal bone disease. Nephrol Dial Transplant 1995;10(Suppl 4):14-8.
  16. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 1993;43:436-42.
  17. Goodman WG. Perspectives on renal bone disease. Kidney Int 2006;70:S59-63.
  18. Block GA. Prevalence and clinical consequences of elevated Ca  P product in hemodialysis patients. Clin Nephrol 2000;54:318-24.
  19. Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nephrologist. Does preventing bone disease cause arterial disease? Kidney Int 2004;66:1315-33.
  20. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int 2005;94(Suppl):S120-7.
  21. Cunningham J, Sprague SM. Osteoporosis Work Group: osteoporosis in chronic kidney dis- ease. Am J Kidney Dis 2004;43:566-71.
  22. Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999;56:1084-93.
  23. Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of ''suppressed'' parathyroid function. Kidney Int 1993;44:860-6.
  24. Sherrard DJ, Hercz G, Pei Y, et al. The aplastic form of renal osteodystrophy. Nephrol Dial Transplant 1996;11(Suppl 3):29-31.
  25. Atsumi K, Kushida K, Yamazaki K, et al. Risk factors for vertebral fractures in renal osteo- dystrophy. Am J Kidney Dis 1999;33:287-93.
  26. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:396-9.
  27. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21.
  28. Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal failure. Kidney Int 2000;58:2200-5.
  29. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
  30. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.
  31. National Kidney Foundation. K-DOQI clinical practice guidelines for bone metabolism and disease. Am J Kidney Dis 2003;42(Suppl 3):S1-202.
  32. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplan- tation. J Am Soc Nephrol 2002;13:551-8.
  33. Reinhardt W, Bartelworth H, Jockenhovel F, et al. Sequential changes of biochemical parameters after kidney transplantation. Nephrol Dial Transplant 1998;13:436-42.
  34. Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differen- tial diagnosis, management and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982;8:92-112.
  35. Alsina J, Gonzales MT, Bonnin R, et al. Long-term evolution of renal osteodystrophy after renal transplantation. Transplant Proc 1989;21:2151-8.
  36. Messa P, Sindici C, Canella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54:1704-13.
  37. Claesson K, Hellman P, Frodin L, et al. Prospective study of calcium homeostasis after renal transplantation. World J Surg 1998;22:635-41.
  38. Evenepoel P, Claes K, Kuyper D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single center study. Nephrol Dial Transplant 2004;19:1281-7.
  39. Saha HH, Salmela KT, Ahonen PJ, et al. Sequential changes in vitamin D and calcium metabolism after successful renal transplantation. Scand J Urol Nephrol 1994;28:21-7.
  40. McCarron DA, Muther RS, Lenfesty B, et al. Parathyroid function in persistent hyperpara- thyroidism: relationship to gland size. Kidney Int 1982;22:662-70.
  41. Lomonte C, Antonelli M, Vernaglione L, et al. Are low plasma levels of 25-(OH) vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant pa- tients? J Nephrol 2005;18:96-101.
  42. De Sevaux RG, Hoitsma AJ, van Hood HJ, et al. Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract 2003;93:C21-8.
  43. Gomez Alonso G, Naves Diaz M, Rodriguez Garcia M, et al. Review of the concept of vitamin D ''sufficiency and insufficiency''. Nefrologia 2003;23(Suppl 2):S73-7.
  44. D'Alessandro AM, Melzer JS, Pirsch JD, et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery 1989;106:1049-55.
  45. Schmid T, Muller P, Spelsberg F. Parathyroidectomy after renal transplantation: a retrospec- tive analysis of long-term outcome. Nephrol Dial Transplant 1997;12:2393-6.
  46. Cundy T, Kanis JA, Heynen G, et al. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983;205:67-8.
  47. Hamdy NAT, Gray RES, McCloskey EV, et al. Clodronate in the medical management of hyperparathyroidism. Bone 1987;8:S69-77.
  48. McGregor D, Burn J, Lynn K, et al. Rapid resolution of tumoral calcinosis after renal trans- plantation. Clin Nephrol 1999;51:54-8.
  49. Ambuhl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement ther- apy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism and acid/base homeostasis. Am J Kidney Dis 1999;34: 875-83.
  50. Levi M. Post-transplant hypophosphatemia. Kidney Int 2001;59:2377-87.
  51. Felsenfeld AJ, Gutman RA, Drezner M, et al. Hypophosphatemia in long-term renal trans- plant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electro- lyte Metab 1986;12:333-41.
  52. Parfitt AM, Kleerekoper M, Cruz C. Reduced phosphate reabsorption unrelated to parathy- roid hormone after renal transplantation: implications for the pathogenesis of hyperparathy- roidism in chronic renal failure. Miner Electrolyte Metab 1986;12:356-62.
  53. Rosenbaum RW, Hruska KA, Korkor A, et al. Decreased phosphate reabsorption after renal transplantation: evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 1981;19:568-78.
  54. Green J, Debby H, Lederer E, et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 2001;60:1182-96.
  55. Riancho JA, de Francisco AL, del Arco C, et al. Serum levels of 1,25-dihydroxyvitamin D after renal transplantation. Miner Electrolyte Metab 1988;14:332-7.
  56. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
  57. Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006;104:23-32.
  58. Bahn I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary ''hyper- phosphatoninism?''. Kidney Int 2006;70:1486-94.
  59. Ghanekar H, Welch BJ, Moe OW, et al. Post-renal transplantation hypophosphatemia: a re- view and novel insights. Curr Opin Nephrol Hypertens 2006;15:97-104.
  60. Falkiewicz K, Nahaczewska W, Boratynska M, et al. Tacrolimus decreases tubular phos- phate wasting in renal allograft recipients. Transplant Proc 2003;35:2213-5.
  61. Carlini RG, Rojas E, Weisinger JR, et al. Bone disease in patients with long-term renal trans- plantation and normal renal function. Am J Kidney Dis 2000;36:160-6.
  62. Monier-Faugere MC, Mawad H, Qi Q, et al. High prevalence of low bone turnover and oc- currence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000;11:1093-9.
  63. Rubin MF, Narins RG. Hypophosphatemia: pathophysiological and practical aspects of its therapy. Semin Nephrol 1990;10:536-45.
  64. Caravaca F, Fernadez MA, Ruiz-Calero R, et al. Effects of oral phosphorus supplementa- tion on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998; 13:2605-11.
  65. Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin Nephrol 2004;24:82-90.
  66. Cunningham J. Post-transplantation bone disease. Transplantation 2005;79:629-34.
  67. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005;90:2456-65.
  68. Hamdy NAT. Osteonecrosis and organ transplantation. In: Compston J, Shane E, editors. Bone disease of organ transplantation. London: Elsevier Academic Press; 2005. p. 353-71.
  69. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991;325:544-50.
  70. Kwan JT, Almond MK, Evans K, et al. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Elec- trolyte Metab 1992;18:166-8.
  71. Epstein S, Inzerillo AM, Caminis J, et al. Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 2003;18:2083-94.
  72. Almond MK, Kwan JT, Evans K, et al. Loss of regional bone mineral density in the first 12 months after renal transplantation. Nephron 1994;66:52-7.
  73. Grotz WH, Mundinger FA, Gugel B, et al. BMD after kidney transplantation: a cross- sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 1995;7:982-6.
  74. Aroldi A, Tarantino A, Montagnino G, et al. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997;63:380-6.
  75. Pichette V, Bonnardeaux A, Prudhomme L, et al. Long-term bone loss in kidney trans- plant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996;28: 105-14.
  76. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid- induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-7.
  77. Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82.
  78. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15:454-7.
  79. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1995;11:1-7.
  80. Grotz W, Mundinger A, Gugel B, et al. Missing impact of cyclosporine on osteoporosis in renal transplant recipients. Transplant Proc 1994;26:2652-3.
  81. McIntyre HD, Menzies B, Rigby R, et al. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimen. Clin Transplant 1995;9:20-4.
  82. Westeel FP, Mazouz H, Ezaitouni F, et al. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 2000;58:1788-96.
  83. Goffin E, Devogelaer JP, Depresseux G, et al. Evaluation of bone mineral density after renal transplantation under a tacrolimus-based immunosuppression: a pilot study. Clin Nephrol 2003;59:190-5.
  84. Goodman GR, Dissanayake IR, Sodam BR, et al. Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 2001;16:72-8.
  85. Kneissel M, Luong-Nguyen N-H, Baptist M, et al. Everolimus suppresses cancellous bone loss, bone formation, and cathepsin K expression by osteoclasts. Bone 2004;35:1144-56.
  86. Durieux S, Mercadal L, Orcel P, et al. BMD and fracture prevalence in long-term kidney graft recipients. Transplantation 2002;74:496-500.
  87. Grotz WH, Mundiger FA, Gugel B, et al. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994;58: 912-5.
  88. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999;14:456-63.
  89. Nisbeth U, Lindh E, Junghall S, et al. Increased fracture rate in diabetes mellitus and in females after renal transplantation. Transplantation 1999;67:1218-22.
  90. Bellorin-Font E, Rojas E, Carlini RG, et al. Bone remodeling after renal transplantation. Kidney Int 2003;63:S125-8.
  91. Cueto-Manzano AM, Konel S, Hutchinson AJ, et al. Bone loss in long-term renal transplan- tation: histopathology and densitometry analysis. Kidney Int 1999;55:2021-9.
  92. Cruz EAS, Lugon JR, Jorgetti V, et al. Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis 2004;44:747-56.
  93. Bravenboer N, Lips P, Holzmann PJ, et al. Bone alkaline phosphatase activity as a predictor of bone histomorphometric parameters of bone turnover a year after successful kidney trans- plantation. J Bone Miner Res 2003;18(Suppl 2):S394.
  94. European best practice guidelines for renal transplantation. Section IV. Long-term manage- ment of the transplant recipient. Nephrol Dial Transplant 2002;17(Suppl 4):43-8.
  95. Palmer S, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2005;18:CD005015.
  96. Weber TJ, Quarles LD. Preventing bone loss after renal transplantation with bisphospho- nates: we can but should we? Kidney Int 2000;57:735-7.